- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04792528
REACT MCI - Repeated Advanced Cognitive Training in Mild Cognitive Impairment (REACT MCI)
Repeated Advanced Cognitive Training in Mild Cognitive Impairment (The REACT MCI Study). A Randomized, Controlled Trial.
Background:
Dementia is a debilitating and devastating disease impacting the individuals, their families, and the health care system. According to the World Health Organization the dementia epidemic could overwhelm the global health care system and undermine social and economic development. Currently, no curative treatment for dementia exists despite immense research activity.
The cognitive and functional impairment in dementia, especially Alzheimer's disease (AD), develop slowly decades before clinical signs emerge. This knowledge has led to the recognition of a prodromal period of mild cognitive impairment (MCI), between normal cognition and dementia. This is at present the earliest stage for intervention in dementia; even a short delay in dementia progression will have a large impact on global economy and health care.
Objectives:
In this clinical multicenter study, we aim to investigate the efficiency and cost-effectiveness of working memory training in MCI. To identify high responders to training analysis of genetic markers, relative's stress and craniospinal clearance will be performed.
Participants and methods:
This study is a blinded, randomized and controlled trail that will include 213 participants, diagnosed with MCI, included from five Norwegian Memory clinics in four health care regions. The groups will be randomized to either two training periods, one training period or active control. The intervention is computerized working memory training. Neuropsychological status, activities of daily living (ADL), and relative stress and quality of life will be assessed at baseline and 3, 6, 12 ,24 and 48 months after training. Structural MRI will be performed at baseline, and 3 and 6 months after training.
For participants in the REACT MCI glymphatics substudy craniospinal clearance will be measured at baseline.
A cost-utility analysis will be performed to evaluate if the working memory training is more cost-effective compared to the active control group in the MCI phase, taking a societal perspective.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mona L Henriksen
- Phone Number: 004737075161
- Email: mona.lonebu.henriksen@sshf.no
Study Contact Backup
- Name: Susanne S Hernes, M.D. Phd.
- Phone Number: 004748136020
- Email: Susanne.sorensen.hernes@sshf.no
Study Locations
-
-
-
Arendal, Norway
- Recruiting
- Sørlandet Sykehus Arendal
-
Contact:
- Susanne L Hernes
- Email: Susanne.sorensen.hernes@sshf.no
-
Contact:
- Mona L Henriksen
-
Bergen, Norway, 5009
- Recruiting
- NKS Olaviken Alderspsykiatriske sykehus - Hukommelsesklinikk
-
Contact:
- Minna Hynninen, MD, Phd
- Email: kia.minna.johanna.hynninen@olaviken.no
-
Bodø, Norway, 8076
- Recruiting
- N.K.S. Kløveråsen
-
Contact:
- Bodil S Olsen
- Email: Bol2@kloverasen.no
-
Oslo, Norway
- Recruiting
- Oslo Universitetssykehus Ullevål
-
Contact:
- Anne Brita Knapskog, MD, Phd
- Email: Anne-brita@knapskog.net
-
Trondheim, Norway, 7006
- Recruiting
- St. Olavs Hospital
-
Contact:
- Rannveig Eldholm, MD, Phd
- Email: Rannveig.s.eldholm@ntnu.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for the REACT MCI study:
- Diagnosis of MCI, based on the Mayo/winblad criteria or confirmation of current MCI status within the last 6 months before study enrollment.
- The ability to use and accessibility to an iPad or computer.
- Fluent in Norwegian.
- Spinal tap performed and results available
Exclusion Criteria for the REACT MCI study:
- Patients unable to undergo a MRI investigation based on claustrophobia or metal foreign bodies are excluded from the study.
- Major psychiatric illness and current substance abuse
- Recent stroke
Inclusion Criteria for the REACT MCI Glymphatics substudy:
- Enrollment in the REACT MCI study
- Participant allocated to Sorlandet Hospital or Oslo University Hospital
Exclusion Criteria for the REACT MCI Glymphatics substudy:
- Individuals with known allergy against contrast solutions
- Individuals with other serious allergies
- Individuals with kidney failure or glomerular filtration rate < 30
- Individuals younger than 18 or older than 80
- Pregnant or lactating women
- For individuals >70 years or with medications affecting kidney function the glomerular filtration rate needs to be less than week old.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: One training period
One training period of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
|
COGMED RM program (Pearson Inc., UK)
|
Experimental: Two training periods
Two training periods of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
|
COGMED RM program (Pearson Inc., UK)
|
Active Comparator: Active control
The generalized brain training group (Active control) will play solitaire 30 minutes daily for 25 sessions
|
Solitaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Working memory training is superior to active control measured by spatial span backwards at 6 months
Time Frame: From enrollment until 6 months
|
From enrollment until 6 months
|
|
Reduced function in the glymphatic system is associated with reduced working memory training effect measured by CT evaluated craniospinal clearance
Time Frame: Enrollment to 12 months
|
Craniospinal clearance will be evaluated with a single CT image scan at level with the foramen magnum.
|
Enrollment to 12 months
|
Working memory training impact quality of life measure in the participants as compared to active control measured by EuroQOL5D-5L after 12 months.
Time Frame: Enrollment to12 months
|
Enrollment to12 months
|
|
Working memory training prolongs the MCI phase as compared to active controls
Time Frame: Enrollment to 48 months
|
We consider the participants as having dementia when they no longer rapport intact activities of daily living and in addition display reduction of 1.5 standard deviation on test score on two tests on three or more cognitive domains.
|
Enrollment to 48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effect of working memory training is dose related measured by spatial span backwards after 6 months
Time Frame: Enrollment to 6 months
|
Enrollment to 6 months
|
|
Allelic variations in predefined genetic markes influence training effects after 3 months measured by spatial span backwards.
Time Frame: Enrollment to 3 months
|
Allelic variations of LMX1a, APOE, AQP4 and/or COMT have in previous publications shown variable impact on working memory training.
A statistical model combining these genes will be fitted for this investigation
|
Enrollment to 3 months
|
Workin memory training reduces relatives stress scores as compared to relatives stress scores in the active control group after 12 months
Time Frame: Enrollment to 12 months
|
Relatives stress score (RSS) is a validated scale measuring the stress for relatives
|
Enrollment to 12 months
|
Working memory training reduces QALY associated cost as compared to active controls at 24 months.
Time Frame: Enrollment to 24 months
|
The generic outcome in the analysis is QALYs (Quality adjusted life years) derived from the instrument EQ-5D 5L.
The second outcome is production loss of the relatives and patients associated with MCI through the progression of dementia The health economic analysis will include following costs: 1) intervention related costs 2) direct costs/health care costs, mainly related to use of health care services, including primary, secondary and tertiary care and health services 3) indirect costs, including work absence for the patients and the relatives of the patients (i.e., productivity loss).
Data will be collected through a self-report measures (EQ-5D 5L), and from the Norwegian patient registry.
|
Enrollment to 24 months
|
Working memory training reduces QALY associated cost as compared to active controls at 48 months.
Time Frame: enrollment to 48 months
|
The generic outcome in the analysis is QALYs (Quality adjusted life years) derived from the instrument EQ-5D 5L.
The second outcome is production loss of the relatives and patients associated with MCI through the progression of dementia The health economic analysis will include following costs: 1) intervention related costs 2) direct costs/health care costs, mainly related to use of health care services, including primary, secondary and tertiary care and health services 3) indirect costs, including work absence for the patients and the relatives of the patients (i.e., productivity loss).
Data will be collected through a self-report measures (EQ-5D 5L), and from the Norwegian patient registry.
|
enrollment to 48 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Susanne S Hernes, M.D. Phd., Sørlandet Sykehus HF, Universitetet i Bergen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 77084 REACT MCI
- Prosjektnr. 2019208 (Other Grant/Funding Number: Program for klinisk forskningsbehandling (KLINBEFORSK))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Centre for Addiction and Mental HealthRecruitingAmnestic Mild Cognitive ImpairmentCanada
-
University of FloridaNational Institute on Aging (NIA)RecruitingAmnestic Mild Cognitive ImpairmentUnited States
-
Charite University, Berlin, GermanyCompletedMild Cognitive Impairment (MCI)Germany
-
Johns Hopkins UniversityNational Institute on Aging (NIA)CompletedMild Cognitive Impairment (MCI)United States
Clinical Trials on Computerized cognitive training.
-
Hadassah Medical OrganizationCompletedAttention Deficit Hyperactivity DisorderIsrael
-
Michigan State UniversityUniversity of Michigan; Global Health Uganda LTDCompleted
-
Rick GuliziaCompletedPosttraumatic Stress Disorder
-
University of BernRecruitingDementia | Alzheimer Disease | Mild Cognitive ImpairmentSwitzerland
-
University of Wisconsin, MilwaukeeRecruitingObsessive-Compulsive Disorder | Skin-Picking | TricholemmomaUnited States
-
Science and Research Centre KoperAlbert Einstein College of Medicine; University of Primorska; Vrije Universiteit...CompletedEffects of Cognitive Intervention on Cognition, Mobility and Brain Electrocortical Activity (GIBKOP)Cognitive Impairment | Aging | Cognitive Decline | Motor Coordination or FunctionSlovenia
-
University of MinnesotaNational Institute of Mental Health (NIMH)RecruitingPsychotic Disorders | Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders | Schizoaffective Disorder | Psychosis | Schizo Affective Disorder | Schizophreniform Disorders | Psychoses, Affective | Psychotic Mood Disorders | Psychosis Nos/OtherUnited States
-
Universidade Federal do Rio de JaneiroUnknown
-
Brigham and Women's HospitalFujifilmRecruitingMild Cognitive Impairment | Acquired Brain Injury | Mild Neurocognitive DisorderUnited States
-
University of Wisconsin, MilwaukeeCompleted